Takeda Pharmaceutical Company Limited

Most Recent

  • uploads///Xtandi
    Company & Industry Overviews

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    How Pfizer’s Sutent and Xalkori Have Performed

    In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.

    By Margaret Patrick
  • uploads///Imbruvica
    Company & Industry Overviews

    A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

    Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter.

    By Daniel Collins
  • uploads///revlimid
    Earnings Report

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

    By Daniel Collins
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///Revlimid
    Earnings Report

    How Are Celgene’s Multiple Myeloma Drugs Positioned before Q2?

    Celgene’s (CELG) Revlimid and Pomalyst generated revenues of $2.2 billion and $453 million, respectively in the first quarter.

    By Daniel Collins
  • uploads///Kyprolis
    Company & Industry Overviews

    Kyprolis Is Expected to Boost Amgen’s Revenue Growth

    In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets.

    By Daniel Collins
  • uploads///medicine _
    Company & Industry Overviews

    Pfizer: Focused on Advancing Oncology Research Programs in 2018

    Pfizer (PFE) plans to produce a second-generation cyclin-dependent kinase (or CDK) inhibitor in 2018.

    By Margaret Patrick
  • uploads///Shire
    Miscellaneous

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.

    By Kenneth Smith
  • uploads///Shire
    Company & Industry Overviews

    Why Shire Stock Rose in the Week Ended March 29

    On March 29, 2018, Shire (SHPG) was trading at $149.39, which represented a 21% rise from its 52-week low of $123.73.

    By Daniel Collins
  • uploads///Gleevec
    Company & Industry Overviews

    How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?

    In 4Q17, Novartis’s (NVS) Gleevec generated revenues of $448 million, which reflected a ~41% decline on year-over-year (or YoY) basis and 1% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Imbruvica
    Company & Industry Overviews

    Johnson & Johnson’s Oncology Segment’s Performance in 2017

    In 4Q17, JNJ’s Velcade reported revenues of $271.0 million compared to $274.0 million in 4Q16, which reflected an ~1.0% YoY decline.

    By Daniel Collins
  • uploads///Remicade
    Company & Industry Overviews

    Performance of Johnson & Johnson’s Remicade and Stelara in 2017

    In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.

    By Daniel Collins
  • uploads///Ibrance
    Company & Industry Overviews

    Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

    In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

    By Daniel Collins
  • uploads///Bosulif
    Company & Industry Overviews

    Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017

    In 4Q17, Pfizer’s (PFE) Bosulif generated revenues of $70 million, which reflected ~52% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///CAR
    Company & Industry Overviews

    A Key Update on Gilead Sciences’ ZUMA-3 Study

    In December 2017, Gilead Sciences (GILD) presented updated results from its ongoing phase-1/2 ZUMA-3 trial.

    By Daniel Collins
  • uploads///Tasigna
    Company & Industry Overviews

    Tasigna Could Boost Novartis’s Revenue Growth in 2018

    In 1Q17, 2Q17, and 3Q17, Tasigna generated revenues of $411 million, $463 million, and $482 million, respectively.

    By Daniel Collins
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Sprycel revenues
    Company & Industry Overviews

    How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?

    In December 2017, Bristol-Myers Squibb presented new data from the phase 2 CA180-372 trial.

    By Daniel Collins
  • uploads///Kyprolis
    Company & Industry Overviews

    Kyprolis Could Boost Amgen’s Revenue Growth in 2018

    in 1Q17, 2Q17, and 3Q17, Kyprolis generated revenues of $190.0 million, $211.0 million, and $207.0 million, respectively.

    By Daniel Collins
  • uploads///Alecensa
    Company & Industry Overviews

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

    By Daniel Collins
  • uploads///Velcade
    Company & Industry Overviews

    How Did JNJ’s Velcade and Procrit Perform in 3Q17?

    In 3Q17, Johnson & Johnson’s (JNJ) Velcade generated revenues of $273 million, a ~10% decline on a year-over-year (or YoY) basis and a 6% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    The Financial Performance of Sucampo Pharmaceuticals

    Sucampo Pharmaceuticals (SCMP) generated revenues of $61.2 million in 3Q17 compared with $57 million in 3Q16.

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Amitiza performance
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Amitiza: Its Performance in 2017

    Sucampo Pharmaceuticals has granted licenses to commercialize a generic or authorized generic of Amitiza in the United States to Par Pharmaceutical and Dr. Reddy’s Laboratories.

    By Kenneth Smith
  • uploads///Nexium
    Company & Industry Overviews

    How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017

    In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

    By Daniel Collins
  • uploads///Sprycel
    Company & Industry Overviews

    How Is Bristol-Myers Squibb’s Sprycel Positioned Now?

    In 3Q17, Bristol-Myers Squibb’s (BMY) Sprycel generated revenues of $509 million, an 8% increase on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Tasigna
    Company & Industry Overviews

    How Novartis’s Tasigna Is Looking Now

    In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Pipeline
    Company & Industry Overviews

    Amgen’s Pipeline Could Boost Its Long-Term Growth Opportunities

    EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

    By Daniel Collins
  • uploads///Gleevec tasigna
    Company & Industry Overviews

    How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?

    In 1H17, Novartis’s (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Binclyto Revenues
    Company & Industry Overviews

    What Amgen Expects from Blincyto in 2017

    Blincyto’s revenue trends In 2Q17, Amgen’s (AMGN) Blincyto generated revenues of ~$43 million, which represented ~43% growth on a YoY (year-over-year) basis. Blincyto (blinatumomab) is an injection for the treatment of adults and children with relapsed or refractory B-cell precursor ALL (acute lymphoblastic leukemia). For more on Blincyto and its revenue prospects, please refer to […]

    By Daniel Collins
  • uploads///Kyprolis Revenues
    Company & Industry Overviews

    What Kyprolis Could Do for Amgen’s Revenue Growth

    Kyprolis’s revenue trends In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed a ~20% volume growth QoQ, and its launch in international markets contributed heavily to the company’s overall YoY revenue growth. In 2Q17, in the US, Kyprolis […]

    By Daniel Collins
  • uploads///Pomalyst
    Company & Industry Overviews

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Revlimid revenues
    Company & Industry Overviews

    Celgene’s Revlimid Witnessed High Growth in 2Q17

    In 2Q17, Celgene’s (CELG) Revlimid generated revenues of ~$2.0 billion, which reflected ~20% growth year-over-year and ~8% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Celgene Quarterly revenues
    Company & Industry Overviews

    How Did Celgene Perform in 1Q17?

    In 1Q17, Celgene (CELG) reported revenues of ~$3.0 billion, an increase of ~18% year-over-year (or YoY).

    By Daniel Collins
  • uploads///Lupron Revenues
    Company & Industry Overviews

    Why Lupron Could Continue to Generate Steady Revenue

    In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

    By Daniel Collins
  • uploads///Kyprolis Revenue
    Company & Industry Overviews

    Exploring Kyprolis’s Revenue Trend in 2017

    In 1Q17, Kyprolis generated revenues of ~$190 million compared to $154 million in 1Q16.

    By Daniel Collins
  • uploads///Kyprolis Clinical Trial Result
    Company & Industry Overviews

    Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017

    Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Relistor May Be Solid Growth Opportunity for Valeant in 2017

    Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Xifaxan Expected to Witness Robust Growth in 2017

    Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US market. Furthermore, the authorized generic version of Zegerid was transferred from Valeant’s Branded Rx segment to the Diversified Products segment. However, these negative trends were […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Merck Continues to Dominate with Its Januvia Franchise

    Despite more competition and pressures, Merck’s Januvia franchise continued to maintain its leadership in the DPP-4 inhibitor class of diabetes drugs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016

    In 3Q16, Valeant Pharmaceuticals’s (VRX) Gastrointestinal product segment witnessed a drop in revenues due to unfavorable changes in drug pricing.

    By Margaret Patrick
  • uploads///salix
    Company & Industry Overviews

    What Might Have Fueled Valeant’s Interest in Salix?

    The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Teva Has a Targeted Strategy to Expand in Major Growth Markets

    In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Strong Brand Positioning Expected to Strengthen Teva’s Position

    Teva Pharmaceutical’s (TEVA) strategy of selectively focusing on certain countries has enabled it to see double-digit organic growth in the growth markets.

    By Margaret Patrick
  • uploads///CHC business position
    Company & Industry Overviews

    Why Is Sanofi Expanding in the CHC Space?

    Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster

    Due to significant unmet demand and limited competition in the women’s health segment, AbbVie expects Elagolix to become a blockbuster therapy.

    By Margaret Patrick
  • uploads///Portfolio Breakdown of the SAESX
    Fund Managers

    SAESX and How It Has Changed in 2016

    Consumer discretionary, information technology, and telecom services form the core of SAESX. Combined, these three form 55% of the fund’s portfolio.

    By David Ashworth
  • uploads///Commonwealth Japan Fund
    Company & Industry Overviews

    Healthcare Stocks Save the Day for CNJFX

    Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Celgene Continues to Develop New Multiple Myeloma Drugs

    Celgene has been working on its immunomodulatory backbone drugs to develop combination therapies for use in treating all lines of multiple myeloma.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Can We Expect from Seattle Genetics’s Adcetris in 1Q16?

    Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.

    By Mike Benson
  • uploads///pharma challenges Japan
    Company & Industry Overviews

    What Are the Challenges for the Pharmaceutical Industry in Japan?

    Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

    By Jillian Dabney
  • uploads///New drug development and approval
    Company & Industry Overviews

    What’s the Drug Approval Process in Japan?

    The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

    By Jillian Dabney
  • uploads///reimbursement approval
    Company & Industry Overviews

    How Are Drugs Priced in Japan?

    The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

    By Jillian Dabney
  • uploads///Alliance in companeis based in US Japan
    Company & Industry Overviews

    Multinational and Japanese Pharmaceuticals Should Build Alliances

    The Japanese pharmaceuticals market is not very welcoming to foreign companies. Similarly, the Japanese population is quite loyal to domestic manufacturers.

    By Jillian Dabney
  • uploads///lialda
    Company & Industry Overviews

    Shire Won Patent Infringement Case for Lialda

    In fiscal 2015, Lialda added $684.4 million to Shire’s (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume.

    By Jillian Dabney
  • uploads///Pipeline for obesity drugs
    Company & Industry Overviews

    How Much Potential Does Saxenda Hold for Novo?

    Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.

    By Jillian Dabney
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///Xifaxan
    Company & Industry Overviews

    Xifaxan: Valeant’s Secret Weapon?

    Xifaxan is indicated for IBS with diarrhea and hepatic encephalopathy. It’s Valeant’s largest revenue generator, contributing ~7.5% of total revenues.

    By Jillian Dabney
  • uploads///Voya Japan TOPIX Index Portfolio Class A
    Company & Industry Overviews

    How Did the Voya Japan TOPIX Index Portfolio Fare in 2015?

    The Voya Japan TOPIX Index Portfolio – Class A (IJIAX) fell 0.9% in December 2015 from the previous month. In the three- and six-month periods ended December 31, the fund has risen 7.3% and fallen 4.0%, respectively.

    By David Ashworth
  • uploads///Brown Advisory WMC Japan Alpha Opportunities Fund
    Company & Industry Overviews

    What Held Back the BIAJX Fund in 2015?

    BIAJX fell 3.7% in December 2015 from the previous month. In the three-month and six-month periods ended December 31, 2015, the fund has risen 8.3% and fallen 6.4%, respectively.

    By David Ashworth
  • uploads///Risk
    Company & Industry Overviews

    Measuring Mylan’s Biggest Risks Moving Forward

    Aside from the risky generic pharmaceutical industry, Mylan faces company-specific business risks like country risk, foreign exchange risk, and M&A risk.

    By Seth Richards
  • uploads///Business Model
    Company & Industry Overviews

    Mylan’s Business Model: A Key Investor Rundown

    In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

    By Seth Richards
  • uploads///Mylan Introduction
    Company & Industry Overviews

    Introducing Mylan, a Big International Gun in Generic Pharmaceuticals

    Headquartered in the UK, Mylan is one of the biggest players in the generic pharmaceutical industry. It was founded by Milan Puskar and Don Panoj in 1961.

    By Seth Richards
  • uploads///Chart
    Miscellaneous

    Eloquent-2: Clinical Study Supports Empliciti’s Approval

    The FDA approval of Empliciti was based on the results of a phase III study termed Eloquent-2.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    FDA Approves Empliciti for Multiple Myeloma

    On November 30, 2015, Bristol-Myers Squibb (BMY) and AbbVie (ABBV) announced that the FDA has approved Empliciti for treatment of patients with multiple myeloma.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Clinical Trials Prove Ninlaro’s Superior Efficacy Profile

    Based on the success of its clinical trial and its superior clinical profile, Takeda’s Ninlaro is expected to prove a tough competitor to other MM drugs.

    By Margaret Patrick
  • uploads///Portfolio Break down of the BIAJX
    Macroeconomic Analysis

    The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX): Overview

    Brown Advisory-WMC Japan Alpha Opportunities Fund doesn’t target a specific segment by market capitalization. Instead, it intends to be benchmark agnostic.

    By David Ashworth
  • uploads///Brown Advisory WMC Japan Alpha Opportunities Fund
    Macroeconomic Analysis

    How the Brown Advisory-WMC Japan Alpha Opportunities Fund Fared in September 2015

    Performance evaluation The Brown Advisory-WMC Japan Alpha Opportunities Fund (BIAJX) fell by 6.7% in September 2015 from the previous month. In the three- and six-month periods ending September 30, the fund fell by 13.5% and 7.7%, respectively. However, in the YTD (year-to-date) period, the fund was up by 2.9%. For all periods mentioned above except […]

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Aims to Establish Strong Presence in Obesity Market

    According to projections by Novo Nordisk (NVO), targeting the obesity market by pharmaceutical companies is about 4–5 DKK (Danish krone currency) in value.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.